Skip to main content

Table 2 Characteristics of trial participants by type of intervention

From: Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials

  Trials All ACT AHT APT CEA GL HRT Statins Vitamins P
All    N = 8 N = 8 N = 7 N = 3 N = 1 N = 2 N = 4 N = 2  
Primary (%) 15   4 (36.7%) 6 (40.0%) 0 1 (6.7%) 1 (6.7%) 2 (13.3%) 1 (6.7%) 0  
Secondary (%) 20   4 (20.0%) 2 (10.0%) 7 (35.0%) 2 (10.0%) 0 0 3 (15.0%) 2 (10.0%)  
Baseline
 Number 35 254,223 54,713 81,058 39,714 5074 10,251 27,347 24,222 11,844  
 Age 35 65.1 (30.5) 69.0 (11.7) 64.6 (51.9) 66.0 (9.6) 66.6 (8.2) 62.8 (6.6) 63.4 (7.2) 59.3 (8.1) 63.7 (12.1) < 0.0001
 Sex, Female (%) 35 117,222 (46.1%) 21,063 (38.5%) 39,213 (48.4%) 14,697 (37.0%) 2711 (53.4%) 3952 (38.6%) 27,347 (100%) 3916 (16.2%) 4323 (36.5%) < 0.0001†
Medical History (%)
 Diabetes 34 51,131 (20.1%) 7030 (12.9%) 17,143 (21.2%) 8897 (22.4%) 1135 (22.4%) 10,251 (100%) 1980 (7.2%) 1725 (7.1%) 2970 (25.3%) < 0.0001‡
 Hypertension 32 153,427 (69.6%) 22,771 (67.0%) 76,550 (94.5%) 25,871 (65.2%) 3212 (63.3%) 8433 (34.0%) 8141 (33.6%) 8449 (72.0%) < 0.0001
 Hyperlipidaemia 17 27,627 (29.8%) 96 (9.6%) 1019 (15.4%) 14,757 (37.3%) 1291 (37.8%) 3366 (13.7%) 4444 (40.2%) 2654 (41.7%) < 0.0001
 IHD 12 27,850 (30.6%) 8813 (24.0%) 6724 (20.7%) 1970 (38.8%) 9014 (100%) 1329 (17.0%) < 0.0001¥
 Stroke 28 21,645 (12.6%) 3403 (9.6%) 5375 (13.9%) 8707 (23.9%) 717 (21.0%) 630 (6.1%) 306 (1.1%) 369 (4.1%) 2138 (18.2%) < 0.0001
 MI 25 22,069 (13.6%) 5073 (14.4%) 704 (2.1%) 2720 (7.7%) 640 (18.8%) 1590 (15.5%) 634 (2.3%) 10,708 (60.8%) < 0.0001
 Smoking, Current 31 48,441 (20.9%) 7030 (21.0%) 17,515 (21.9%) 10,211 (25.8%) 1471 (29.0%) 1247 (12.2%) 2831 (10.5%) 3496 (14.4%) 4640 (39.5%) < 0.0001
 Alcohol 12 27,897 (41.3%) 6373 (34.2%) 4754 (48.0%) 10,984 (40.5%) 561 (33.8%) 3098 (46.9%) 2127 (59.4%) < 0.0001
 SBP 31 145.8 (23.1) 143.5 (27.1) 155.2 (19.8) 147.4 (20.2) 146.1 (19.3) 128.7 (17.6) 136.5 (18.8) 141.5 (20.9) < 0.0001
 DBP 30 83.3 (12.0) 79.5 (12.8) 87.7 (11.1) 84.9 (11.7) 80.1 (10.0) 76.0 (9.2) 80.3 (10.4) 81.6 (12.1) < 0.0001
 HR 14 73.1 (13.7) 75.1 (15.8) 77.5 (11.6) 73.2 (12.4) 73.1 (10.6) 67.8 (11.1) < 0.0001
Secondary
 Qualifying event (%)
  Stroke 19 71,178 (66.4%) 19,779 (60.9%) 5632 (85.2%) 34,071 (85.8%) 1571 (46.0%) 10,125 (86.1%) < 0.0001
  MI 19 25,528 (22.9%) 12,090 (37.2%) 1348 (76.3%) < 0.0001
  TIA 19 9979 (9.3%) 347 (1.1%) 974 (14.7%) 5497 (13.8%) 1759 (51.6%) 1402 (11.9%) < 0.0001
  OTR 18 91.2 (246.2) 3.2 (12.9) 418.0 (439.6) 31.0 (163.5) 47.9 (43.6) 507.4 (317.0) 60.2 (178.0) < 0.0001
  1. ACT: anticoagulants; AHT: antihypertensives; APT: antiplatelets; CEA: carotid endarterectomy; DBP: diastolic blood pressure; GL: glucose lowering; HRT: hormone replacement therapy; IHD: ischaemic heart disease; MI: myocardial infarction; HR: heart rate; OTR: onset to randomisation; SBP: systolic blood pressure; TIA: transient ischaemic attack. Percentages (%) are out of the total number of participants with available data. Comparisons by Chi-Square test and ANOVA. †Excluding HRT group. ‡Excluding GL group. ¥Excluding Statins group